Table of Contents
Hepatitis Research and Treatment
Volume 2010, Article ID 817580, 17 pages
Review Article

Therapeutic Vaccination in Chronic Hepatitis B: Preclinical Studies in the Woodchuck

Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Virchowstra╬▓e 179, 45122, Essen, Germany

Received 7 June 2010; Accepted 29 July 2010

Academic Editor: Yoichi Hiasa

Copyright © 2010 Anna D. Kosinska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Recommended treatment of chronic hepatitis B with interferon- and/or nucleos(t)ide analogues does not lead to a satisfactory result. Induction of HBV-specific T cells by therapeutic vaccination or immunotherapies may be an innovative strategy to overcome virus persistence. Vaccination with commercially available HBV vaccines in patients did not result in effective control of HBV infection, suggesting that new formulations of therapeutic vaccines are needed. The woodchuck (Marmota monax) is a useful preclinical model for developing the new therapeutic approaches in chronic hepadnaviral infections. Several innovative approaches combining antiviral treatments with nucleos(t)ide analogues, DNA vaccines, and protein vaccines were tested in the woodchuck model. In this paper we summarize the available data concerning therapeutic immunization and gene therapy using recombinant viral vectors approaches in woodchucks, which show encouraging results. In addition, we present potential innovations in immunomodulatory strategies to be evaluated in this animal model.